Endothelin-1 impairs nitric oxide signaling in endothelial cells through a protein kinase cδ-dependent activation of STAT3 and decreased endothelial nitric oxide …

N Sud, SM Black - DNA and cell biology, 2009 - liebertpub.com
N Sud, SM Black
DNA and cell biology, 2009liebertpub.com
In an ovine model of persistent pulmonary hypertension of the newborn (PPHN), endothelin-
1 (ET-1) expression is increased, while endothelial nitric oxide synthase (eNOS) expression
is decreased. However, the molecular mechanisms by which ET-1 attenuates eNOS
expression in endothelial cells are not completely understood. Thus, the goal of this study
was to determine if the overexpression of ET-1 decreases eNOS expression in pulmonary
arterial endothelial cells isolated from fetal lambs. To increase the ET-1 expression, cells …
In an ovine model of persistent pulmonary hypertension of the newborn (PPHN), endothelin-1 (ET-1) expression is increased, while endothelial nitric oxide synthase (eNOS) expression is decreased. However, the molecular mechanisms by which ET-1 attenuates eNOS expression in endothelial cells are not completely understood. Thus, the goal of this study was to determine if the overexpression of ET-1 decreases eNOS expression in pulmonary arterial endothelial cells isolated from fetal lambs. To increase the ET-1 expression, cells were transfected with a plasmid coding for Prepro-ET-1, a precursor of ET-1. After overexpression of Prepro-ET-1, ET-1 levels in the culture medium were significantly increased (control = 805.3 ± 69.8; Prepro-ET-1 overexpression = 1351 ± 127.9). eNOS promoter activity, protein levels, and NO generation were all significantly decreased by the overexpression of Prepro-ET-1. The decrease in transcription correlated with increased activity of protein kinase Cδ (PKCδ) and STAT3. Further, DNA binding activity of STAT3 was also increased by Prepro-ET-1 overexpression. The increase in STAT3 activity and decrease in eNOS promoter activity were inhibited by the overexpression of dominant negative mutants of PKCδ or STAT3. Further, a 2 bp mutation in the STAT3 binding site in the eNOS promoter inhibited STAT3 binding and led to enhanced promoter activity in the presence of Prepro-ET-1 overexpression. In conclusion, ET-1 secretion is increased by Prepro-ET-1 overexpression. This results in activation of PKCδ, which phosphorylates STAT3, increasing its binding to the eNOS promoter. This in turn decreases eNOS promoter activity, protein levels, and NO production. Thus, ET-1 can reduce eNOS expression and NO generation in fetal pulmonary artery endothelial cells through PKCδ-mediated activation of STAT3.
Mary Ann Liebert